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Abstract
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or in the miRNA binding sites
may affect the miRNA dependent gene expression regulation, which has been implicated in various cancers, including
breast cancer, and may alter individual susceptibility to cancer. We investigated associations between miRNA related SNPs
and breast cancer risk. First we evaluated 2,196 SNPs in a case-control study combining nine genome wide association
studies (GWAS). Second, we further investigated 42 SNPs with suggestive evidence for association using 41,785 cases and
41,880 controls from 41 studies included in the Breast Cancer Association Consortium (BCAC). Combining the GWAS and
BCAC data within a meta-analysis, we estimated main effects on breast cancer risk as well as risks for estrogen receptor (ER)
and age defined subgroups. Five miRNA binding site SNPs associated significantly with breast cancer risk: rs1045494 (odds
ratio (OR) 0.92; 95% confidence interval (CI): 0.88–0.96), rs1052532 (OR 0.97; 95% CI: 0.95–0.99), rs10719 (OR 0.97; 95% CI:
0.94–0.99), rs4687554 (OR 0.97; 95% CI: 0.95–0.99, and rs3134615 (OR 1.03; 95% CI: 1.01–1.05) located in the 39 UTR of CASP8,
HDDC3, DROSHA, MUSTN1, and MYCL1, respectively. DROSHA belongs to miRNA machinery genes and has a central role in
initial miRNA processing. The remaining genes are involved in different molecular functions, including apoptosis and gene
expression regulation. Further studies are warranted to elucidate whether the miRNA binding site SNPs are the causative
variants for the observed risk effects.
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Introduction
Breast cancer is the most common women’s cancer and is a
leading cause of cancer mortality [1]. Inherited genetic variation
has been associated with the initiation, development and
progression of breast cancer. Studies on twins have suggested that
hereditary predisposing factors are involved in up to one third of
all breast cancers [2]. Many genetic loci have been associated with
breast cancer risk and collectively explain approximately 35% of
the familial risk [3,4]. The largest genetic association study of
breast cancer to date identified 41 novel low penetrance
susceptibility loci [4] by selecting nearly 30,000 SNPs from a
meta-analysis of nine genome-wide association (GWA) studies and
genotyping them using 41,785 cases and 41,880 controls of
European ancestry from studies in the Breast Cancer Association
Consortium (BCAC). These 41 susceptibility loci probably
represent the tip of the ice berg, and additional SNPs from the
combined GWAS might explain a similar fraction of familial risk
to that attributed to the already identified loci [4].
Mature miRNAs are 20–23 nucleotide, single-stranded RNA
molecules that play a crucial role in gene expression regulation for
many cellular processes including differentiation potential and
development pattern. MiRNAs undergo a stepwise maturation
process involving an array of miRNA machinery components.
Drosha and DGCR8 mediate the cleavage of long primary
miRNA transcripts (pri-miRNAs) into shorter pre-miRNAs in the
nucleus [5,6]. The pre-miRNAs are then transported to the
cytoplasm where they are further cleaved by Dicer to produce
mature miRNAs [7]. MiRNAs interact by pairing with the 39
untranslated region (UTR), and also within the coding region and
59 UTR of the corresponding mRNAs leading to mRNA
destabilization, cleavage or translation repression. More effective
mRNA destabilization is achieved when miRNA targets the
3’UTR rather than other mRNA regions [8–10]. An individual
miRNA may regulate approximately 100 distinct mRNAs, and
together more than 1000 human miRNAs are believed to
modulate more than half of the mRNA species encoded in the
genome [11,12]. Additionally, most mRNAs possess binding sites
for miRNAs [13]. MiRNAs are involved in tumorigenesis in that
they can be either oncogenic when tumor suppressor genes are
targeted, or genomic guardians (tumour suppressor miRNAs)
when oncogenes are targeted [14]. Additionally it has been
suggested that they may modulate both metastasis [15] and
chemotherapy resistance [16]. MiRNAs have also been shown to
have altered expression levels in tumours compared to normal
tissue and between tumor subtypes in breast cancer among other
carcinoma types [17–19]. SNPs may affect miRNA machinery
genes or miRNAs activity; however SNPs can also create, abolish
or modify miRNA binding sites in their binding regions.
Polymorphisms in miRNA binding sites have been studied in
regard to the risk of several cancers [20], including breast cancer
[21–23]. These studies have found evidence for association of
miRNA related SNPs and cancer risk, but the study sample sizes
have been relatively small.
In this study, we investigate associations between miRNA-
related polymorphisms and breast cancer risk by using a meta-
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analysis of nine GWAS and subsequent genotyping of top hits
using 41,785 cases and 41,880 controls of European ancestry from
the BCAC. To our knowledge, this is thus far the largest
investigation of associations between miRNA-related polymor-
phisms and breast cancer susceptibility.
Materials and Methods
SNP selection and genotyping
SNPs in mature or pre-miRNAs, in genes of the miRNA
machinery and in 3’UTR regions of protein coding genes with a
potential effect on miRNA binding were systematically searched
from Ensembl (hg18/build36) and Patrocles databases [24].
Additionally, tagging SNPs for such with r2$0.8 were also
identified utilizing the public HapMap SNP database. By this in
silico approach we identified altogether 147,801 candidate SNPs
and 12,550 tagging SNPs. These SNPs were then overlayed with
those from the combined GWAS from the BCAC [4] and
altogether 2196 SNPs were present (either genotyped or imputed)
in the combined GWAS. These SNPs were genotyped with
Illumina or Affymetrix arrays, as described previously [25–32].
The combined GWAS data were imputed for all scans using
HapMap version 2 CEU as a reference in similar fashion to that
presented by Michailidou and colleagues [4] with the exception
that the HapMap version 2 release 21 was used at the time the
overlay was performed. Analysis using a 1-degree-of-freedom
trend test of these 2196 SNPs in the combined GWAS indicated
some evidence of association with breast cancer risk for 44 SNPs
(p,0.09). Notably, the combined GWAS included imputed data
generated using HapMap version 2 release 21 (based on NCBI
build 35 (dbSNP b125)), whereas the results presented here for the
combined GWAS are based on imputation using HapMap version
2 release 22 (based on NCBI build 36 (dbSNP b126)). In the
release 22, a number of SNPs were excluded due to mapping
inconsistencies in build 35 relative to build 36. Hence, the
estimates from the combined GWAS may slightly differ from the
initial association analysis. The 44 SNPs (including 30 candidate
and 14 tagging SNP) were genotyped on additional samples in the
BCAC using the custom Illumina Infinium array (iCOGS) which
included a total of 211,155 SNPs as described previously. The
detailed description of quality control process for combined
GWAS and iCOGS genotyping data was presented in [4].
Of the 42 SNPs that passed quality control [4], two were
located in miRNA genes (one candidate SNP located in pre-
miRNA hsa-miR-2110 and one tag SNP tagging a mature hsa-
mir-548l variant), and four SNPs were located in miRNA
machinery genes (SMAD5, SND1, CNOT4 and DROSHA).
The genotyped DROSHA SNP tags the 39 UTR miRNA binding
site variant in the DROSHA gene. The remaining 38 candidate or
tag SNPs were located in, or tagged to a predicted miRNA binding
site in the 39 UTR of protein coding genes. All 42 SNPs are
described in Table 1. The workflow of the SNP selection in
different stages is illustrated in Figure 1.
Study sample
The combined GWAS included nine breast cancer studies
totalling 10,052 cases and 12,575 controls of European ethnic
background. Details and study-specific subject numbers are
presented in Table S1. Since the GWAS were limited to patients
of European ethnic background we further utilized 41,785 cases
ascertained for their first primary, invasive breast cancer and
41,880 controls of European ancestry from 41 BCAC studies
genotyped using the iCOGS array (Table S2). For a subgroup
analysis of ER negative and ER positive cases, as well as cases aged
less than 50 years at diagnosis, we included all the cases for which
the respective data were available. The ER subgroup analysis was
based on 702 ER negative cases and 2,019 ER positive cases from
five GWAS studies and 7,200 ER negative cases from 40 BCAC
studies and 26,302 ER positive cases from 34 BCAC studies. The
analysis of cases aged less than 50 years at diagnosis was based on
3,470 cases from three GWAS studies and 9,483 cases from
35 BCAC studies. All participating studies conform to the
Declaration of Helsinki and were approved by the respective
ethical review boards and ethics committees (Tables S1 and S2),
and all participants in these studies had provided written consent
for the research.
Statistical methods
We used logistic regression to estimate per-allele log-odds ratios
and standard errors including the study as a covariate. We also
included principal components as covariates in order to correct for
potential hidden population structure. In the GWAS, for two
studies (UK2 and HEBCS) the estimates were adjusted for the first
three principal components and in the iCOGS analysis we used
the first six principal components and an additional component to
reduce inflation for the LMBC study, as described previously [4].
Subgroup analyses were carried out for ER negative and positive
subgroups and for the group aged less than 50 years at diagnosis.
For meta-analysis, we combined the estimates from the combined
GWAS and iCOGS with a fixed effects model using the inverse
variance weighted method. In the meta-analysis, the subjects
involved in both combined GWAS and iCOGS (1880) were only
taken into account once. In order to adust for P-values against
multiple testing, we used Benjamini Hochberg correction. The
adjusted P-values are shown in Table 2 along with the nominal P-
values. In the text we report the nominal P-values. The statistical
analyses were conducted using the R 2.14.0 statistical computing
environment (http://www.r-project.org/).
Results
For the 42 SNPs we successfully genotyped, estimates of
association from the combined GWAS and from iCOGS analysis
are shown in Table S3. Twenty-one SNPs showed consistent
Figure 1. Workflow of miRNA SNP selection.
doi:10.1371/journal.pone.0109973.g001
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associations with breast cancer risk in the combined GWAS and in
iCOGS analysis; results from the meta-analysis are shown in
Table 2. The most significantly associated SNP, rs702681 (OR
1.06 [95%CI 1.04–1.08]; P 3.9610210), is located in the 3’UTR
of MIER3, close to the known breast cancer susceptibility gene
MAP3K1. The SNP rs702681 is located at the same 5q11.2 locus
as the previously published risk SNP rs889312 [33] (correlation
r2 = 0.3). When the two SNPs were analysed in the same logistic
regression model, the association with rs889312, but not that with
rs702681 remained nominally statistically significant, suggesting
that rs702681 is unlikely to be the causal SNP at this locus. The
five SNPs with the significant novel associations from the meta-
analysis (P#5.0761023and adjusted P#3.5561022 after correc-
tion for multiple testing) were rs1045494, (OR 0.92 [95%CI 0.88–
0.96]; P= 5.9061025), rs1052532, (OR 0.97 [95%CI 0.95–0.99];
P= 7.7861024), rs10719, (OR 0.97 [95%CI 0.94–0.99];
P= 1.3561023) rs4687554 (OR 0.97 [95%CI 0.95–0.99];
P= 1.7161023) and rs3134615 (OR 1.03 [95%CI 1.01–1.05];
P= 5.0761023) located in 39 UTR of Caspase-8 (CASP8), HD
Domain Containing 3 (HDDC3), DROSHA, Musculoskeletal,
Embryonic Nuclear Protein 1 (MUSTN1) and V-Myc Myelocy-
tomatosis Viral Oncogene Homolog 1 (MYCL1), respectively
(Table 2). SNP rs1045494 is tagging the hsa-miR-938 binding site
SNP rs1045487 (r2 = 1.0) of CASP8 and the SNP rs1052532 in
HDDC3 is predicted to abolish the binding site for hsa-miR-1224-
3p. The SNP rs10719 is predicted to abolish the hsa-miR-1298
binding site in the 39 UTR of DROSHA. SNP rs4687554 tags the
hsa-miR-891b binding site SNP rs6445538 (r2 = 1.0) of MUSTN1
and rs3134615 is located at the binding site of hsa-miR-1827 of
MYCL1. There was no evidence for heterogeneity in the per-allele
OR for any SNP. The per study per allele ORs for these five
miRNA binding site SNPs from the combined GWAS along with
per-SNP heterogeneity variance P-values are shown in Figure S1
and from the iCOGS in Figure S2. Next we analysed the SNPs by
ER status-defined subtype, and for cases aged less than 50 years at
diagnosis, for risk associations in the meta-analysis of combined
GWAS and iCOGS (Tables S4, S5 and S6). These analyses did
not reveal any additional significant results. For rs1045494 in
CASP8, rs4687554 in MUSTN1 and rs3134615 in MYCL1 (OR
1.03 [95%CI 1.01–1.05]; P= 7.7561024) a more significant
association with breast cancer risk was found for the ER positive
subgroup than in the main analysis, but the result from the test for
heterogeneity by ER status was not significant (data not shown).
All associations were estimated using an additive inheritance
model. Dominant and recessive models did not improve the
estimates (data not shown).
Discussion
We investigated associations between genetic variation in
miRNAs, in the genes of the miRNA machinery and in the
miRNA binding sites and the risk of breast cancer. We identified
several SNPs that are predicted to abolish an miRNA binding site
and that are significantly associated with breast cancer risk.
Previous studies investigating miRNA related SNPs, especially in
miRNA binding sites have included predefined sets of genes.
Nicoloso and colleagues investigated 38 previously identified
breast cancer risk SNPs and found two to modify miRNA binding
sites in TGFB1 and XRCC1 in vitro [23]. Neither of these were
included in our data set. Liang and colleagues investigated 134
potential miRNA binding sites in cancer-related genes and found
six miRNA binding site SNPs that were associated with ovarian
cancer risk [34].T
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In the meta-analysis of combined GWAS and iCOGS for main
effects, for four of the five most significant miRNA binding site
SNPs, the minor allele was associated with a decreased breast
cancer risk. The minor allele of SNP rs3134615 in 39 UTR of
MYCL1 was associated with an increased breast cancer risk. All
the five most significant miRNA binding site SNPs locate in 39
UTR and have been predicted to abolish the miRNA binding site.
The defect in miRNA-mediated regulation would be expected to
lead to an increase in the translation of the corresponding encoded
protein. The five genes, whose regulation may be affected by the
miRNA-associated SNPs, include the pre-apoptotic gene CASP8,
HDDC3, miRNA biogenesis master regulator DROSHA, MYC-
family member MYCL1 and MUSTN1. CASP8 is involved in
apoptosis in breast cancer cells [35], and many studies have
reported polymorphisms in this gene to be associated with risks for
several cancers [36,37] including breast cancer [38,39], indicating
the importance of CASP8 in tumor development. SNP rs1045494
studied here is located close to the coding region SNP rs1045485
that has been previously shown to have a stronger protective effect
[38,40,41]. Interestingly, Michalidou and colleagues reported this
SNP as having only weak evidence for an association (P 0.0013 in
combined GWAS and iCOGS) [4], but these two SNPs
(rs1045485 and rs1045494) are not correlated (r2 = 0.001 in
Caucasian population). Neither is rs1045494 correlated with the
more strongly associated rs1830298 SNP, identified through fine-
mapping of the region (r2 = 0.02) [42]. Rs1045494 tags SNP
rs1045487 (r2 = 1.0) which is predicted to abolish the hsa-miR-938
binding site and thus may affect CASP8 expression. There is very
little reported evidence on the involvement of HDDC3 or the hsa-
miR-1224-3p in cancer, indicating a novel association with risk.
HDDC3 has been suggested to be involved in the starvation
response [43]. The HDDC3 gene is expressed at higher levels by
several different tumor types, including breast tumors, than by
normal tissue [44]. DROSHA is a miRNA master regulator. It is a
member of the RNase III enzyme family, belongs to the miRNA
biogenesis pathway and is the core nuclease that processes pri-
miRNAs into pre-miRNAs in the nucleus [5,6]. The SNP rs10719
in the 39 UTR of DROSHA is predicted to abolish the hsa-miR-
1298 binding site. Hsa-miR-1298 is predicted to target DROSHA
by the Patrocles prediction as well as by TargetScan [45] and
PITA [46] prediction algorithms. Recently a small Korean study
reported another SNP rs644236, tagging the SNP rs10719
(r2 = 0.955 in CEU population and r2 = 0.876 in Asian population
(combined CHB and JPT)) to be associated with elevated breast
cancer risk [47]. When taking into account the opposite major and
minors alleles in the Asian and European populations for SNPs
rs644236 and rs10719, this result is in concordance with our
results where both the combined GWAS as well as the iCOGS
analysis consistently indicated an association of the minor allele of
SNP rs10719 with reduced breast cancer risk. We also found the
minor allele of SNP rs3134615 in the 39 UTR of MYCL1 to be
associated with an increased risk. MYCL1 (L-MYC) belongs to the
same family of transcription factors as the known proto-oncogene
MYC (C-MYC) and they share a high degree of structural
similarity [48]. The MYCL1 gene has previously been reported to
be amplified and overexpressed in ovarian cancer [49]. A case-
control study by Xiong and colleagues reported SNP rs3134615 to
be significantly associated with increased risk of small cell lung
cancer [50]. SNP rs3134615 was predicted by Patrocles to abolish
the hsa-miR-1827 binding site. This has also been suggested by
functional studies where MYCL1 was found as the target of hsa-
miR-1827 and the SNP rs3134615 was also found to increase
MYCL1 expression [50]. The evidence from functional studies is
consistent with our finding that SNP rs3134615 might increase
breast cancer risk. MUSTN1 has been shown to be involved in the
development and regeneration of the musculoskeletal system [51].
Thus far no evidence of association between MUSTN1 and breast
cancer has been reported, but the MUSTN1 gene is expressed in
the mammary glands [52].
Since only a small fraction of miRNA binding sites has been
experimentally validated, we selected SNPs that had been
computationally predicted to affect miRNA binding sites. For
our original SNP selection we used the Patrocles database that
contains predicted miRNA binding sites and also compiles
perturbation prediction of SNP effects. There are a multitude of
prediction programs and their performance has been evaluated
[53]. Witkos and colleagues find target prediction algorithms that
utilize orthologous sequence alignment, like Patrocles, to be the
most reliable.
The followup of the 42 miRNA related SNPs identified five
significant associations with breast cancer risk. Although the
individual risk effects were subtle, considering that we could only
investigate a small proportion of our initial in silico data set of
miRNA related SNPs (over 140,000 SNPs) this may suggest that
genetic polymorphisms affecting the miRNA regulation could
have a considerable combined effect on breast cancer risk.
It should be noted that, until fine mapping studies are carried
out for these loci, it is not clear whether these miRNA-related
SNPs are the variants responsible for the observed associations.
This comprehensive analysis of miRNA related polymorphisms
using a large two stage study of women with European ancestry
provides evidence for miRNA related SNPs being potential
modulators of breast cancer risk.
Supporting Information
Figure S1 Forest plots for the five most significant
miRNA binding site SNPs from the combined GWAS.
Squares indicate the estimated per-allele OR for the minor allele
in Europeans. The horizontal lines indicate 95% confidence limits.
The vertical blue dashed lines indicate clipping of the confidence
intervals for presentation purpose. The area of the square is
inversely proportional to the variance of the estimate. The
diamond indicates the estimated per-allele OR from the combined
analysis.
(PDF)
Figure S2 Forest plots for the five most significant
miRNA binding site SNPs from the iCOGS. Squares
indicate the estimated per-allele OR for the minor allele in
Europeans. The horizontal lines indicate 95% confidence limits.
The vertical blue dashed lines indicate clipping of the confidence
intervals for presentation purpose. The area of the square is
inversely proportional to the variance of the estimate. The
diamond indicates the estimated per-allele OR from the combined
analysis.
(PDF)
Table S1 A description of each GWAS study, number of
subjects and genotyping platform used in combined
GWAS.
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subjects of European origin in iCOGS.
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Table S3 Frequencies and effect sizes of the 42 SNPs in
the main analysis; combined GWAS and iCOGS.
(DOC)
PLOS ONE | www.plosone.org 9 November 2014 | Volume 9 | Issue 11 | e109973
MicroRNA Related Polymorphisms and Breast Cancer Risk
Table S4 Results for SNPs in the GWAS and iCOGS
separately and combined GWAS+iCOGS analysis for ER
negative subgroup.
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Table S5 Results for SNPs in the GWAS and iCOGS
separately and combined GWAS+iCOGS analysis for ER
positive subgroup.
(DOC)
Table S6 Results for SNPs in the GWAS and iCOGS
separately and combined GWAS+iCOGS analysis for
cases less than 50 years at diagnosis.
(DOC)
Acknowledgments
We thank all the individuals who took part in these studies and all the
researchers, study staff, clinicians and other health care providers,
technicians and administrative staff who have enabled this work to be
carried out. The HEBCS thanks Dr. Karl von Smitten and RN Irja
Erkkila¨ for their help with the HEBCS data and samples. The ABCFS
thanks Maggie Angelakos, Judi Maskiell and Gillian Dite. The OFBCR
thanks Teresa Selander, Nayana Weerasooriya and Gord Glendon. The
ABCS would like to acknowledge Ellen van der Schoot for DNA of
controls. The BBCC thanks Silke Landrith, Sonja Oeser, Matthias
Ru¨bner. The BBCS thanks Eileen Williams, Elaine Ryder-Mills and Kara
Sargus. The BIGGS thanks Niall McInerney, Gabrielle Colleran, Andrew
Rowan and Angela Jones. The BSUCH thanks Peter Bugert and the
Medical Faculty, Mannheim. The CGPS thanks the staff and participants
of the Copenhagen General Population Study, and Dorthe Uldall
Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldga˚rd Hansen
for excellent technical assistance. The CNIO-BCS acknowledge the
support of Nuria A´lvarez, Daniel Herrero, Primitiva Menendez and the
Human Genotyping-CEGEN Unit (CNIO). The DFBBCS thanks
Margreet Ausems, Christi van Asperen, Senno Verhoef, and Rogier van
Oldenburg for providing samples from their Clinical Genetic centers. We
also thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and
Marjolein Peters for their help in creating the GWAS database, and Karol
Estrada and Maksim V. Struchalin for their support in creation and
analysis of imputed data. The authors are grateful to the study participants,
the staff from the Rotterdam Study and the participating general
practitioners and pharmacists. The ESTHER thanks Hartwig Ziegler,
Sonja Wolf and Volker Hermann, Katja Butterbach. The GC-HBOC
would like to thank the following persons for providing additional
information and samples: Prof. Dr. Norbert Arnold, Dr. Sabine Preissler-
Adams, Dr. Monika Mareeva-Varon, Dr. Dieter Niederacher, Prof. Dr.
Brigitte Schlegelberger, Dr. Clemens Mu¨l, Heide Hellebrand, and Stefanie
Engert. The HMBCS thanks Peter Hillemanns, Hans Christiansen and
Johann H. Karstens. The KBCP thanks Eija Myo¨ha¨nen and Helena
Kemila¨inen. kConFab/AOCS wish to thank Heather Thorne, Eveline
Niedermayr, all the kConFab research nurses and staff, the heads and staff
of the Family Cancer Clinics, and the Clinical Follow Up Study for their
contributions to this resource, and the many families who contribute to
kConFab. The LMBC thanks Gilian Peuteman, Dominiek Smeets,
Thomas Van Brussel and Kathleen Corthouts. The MARIE would like
to thank Alina Vrieling, Katharina Buck, Ursula Eilber, Muhabbet Celik,
and Sabine Behrens. The MBCSG thanks Siranoush Manoukian, Bernard
Peissel and Daniela Zaffaroni of the Fondazione IRCCS Istituto Nazionale
dei Tumori (INT); Bernardo Bonanni, Irene Feroce and Angela
Maniscalco of the Istituto Europeo di Oncologia (IEO) and the personnel
of the Cogentech Cancer Genetic Test Laboratory. The MTLGEBCS
gratefully acknowledge the assistance of Lesley Richardson and Marie-
Claire Goulet in conducting the study. We would like to thank Martine
Tranchant (Cancer Genomics Laboratory, CHU de Que´bec Research
Center), Marie-France Valois, Annie Turgeon and Lea Heguy (McGill
University Health Center, Royal Victoria Hospital; McGill University) for
DNA extraction, sample management and skillful technical assistance. J.S.
is Chairholder of the Canada Research Chair in Oncogenetics. The
OBCS thanks Meeri Otsukka and Kari Mononen. The ORIGO thanks E.
Krol-Warmerdam, and J. Blom for patient accrual, administering
questionnaires, and managing clinical information. The LUMC survival
data were retrieved from the Leiden hospital-based cancer registry system
(ONCDOC) with the help of Dr. J. Molenaar. The OSU thanks Robert
Pilarksi and Charles Shapiro, who were instrumental in the formation of
the OSU Breast Cancer Tissue Bank. We thank the Human Genetics
Sample Bank for processing of samples. OSU Columbus area control
specimens were provided by the Ohio State University’s Human Genetics
Sample Bank. The PBCS thanks Mark Sherman, Neonila Szeszenia-
Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao and Michael
Stagner. The RBCS thanks Petra Bos, Jannet Blom, Ellen Crepin, Anja
Nieuwlaat, Annette Heemskerk and the Erasmus MC Family Cancer
Clinic. The SBCS thanks Sue Higham, Ian Brock, Sabapathy Balasu-
bramanian, Helen Cramp and Dan Connley. The SEARCH thanks the
SEARCH and EPIC-Norfolk teams. The iCOGS study would not have
been possible without the contributions of the following: Qin Wang
(BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Ali Amin Al
Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Antonis
Antoniou, Lesley McGuffog and Ken Offit (CIMBA), Andrew Lee, and
Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic
Epidemiology Laboratory, Anna Gonzalez-Neira and the staff of the
CNIO genotyping unit, Daniel C. Tessier, Francois Bacot, Daniel Vincent,
Sylvie LaBoissie`re and Frederic Robidoux and the staff of the McGill
University and Ge´nome Que´bec Innovation Centre, and the staff of the
Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A.
Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo
Clinic Genotyping Core Facility.
Consortia members
GENICA Network. Hiltrud Brauch, Wing-Yee Lo, Christina
Justenhoven: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharma-
cology, Stuttgart, and University of Tu¨bingen, Germany. Yon-Dschun Ko,
Christian Baisch: Department of Internal Medicine, Evangelische Kliniken
Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. Hans-Peter
Fischer: Institute of Pathology, University of Bonn, Bonn, Germany. Ute
Hamann: Molecular Genetics of Breast Cancer, Deutsches Krebs-
forschungszentrum (DKFZ), Heidelberg, Germany. Thomas Bru¨ning,
Beate Pesch, Sylvia Rabstein, Anne Lotz: Institute of the Ruhr University
Bochum (IPA), Bochum, Germany. Volker Harth: Institute for Occupa-
tional Medicine and Maritime Medicine, University Medical Center
Hamburg-Eppendorf, Germany.
kConFab Investigators. See http://www.kconfab.org/Organisation/
Members.aspx
AOCS. See http://www.aocstudy.org/org_coll.asp
Author Contributions
Conceived and designed the experiments: HN DG GCT AC RLM DFE
SK KM JCC AD MS MGC PH. Performed the experiments: SK DG KM
RLM DFE. Analyzed the data: SK DG KM RLM HN DFE. Contributed
reagents/materials/analysis tools: SK HN DG KM GCT AC RLM PDPP
UH MKS A. Meindl RW TH CB K. Aaltonen GGG DFE PAF MJH ILA
H. Brauch QW EJS H. Brenner AKD MSG FL TAM K. Aittoma¨ki J. Liu
PH AI KH J. Li KC JCC RH AR PS DFJ OF JP IdSS NJ LG ZA JLH HT
M. Bui EM DFS MCS CA J. Stone HMH MAA RBvdL A. Mannermaa
RKS BMM PL CT NR SJC DJH SSC MWRR AB LJVV FBH MGS
ABE MWB SEB BGN SFN HF PMZ JIAP J. Benitez CAH BEH FS LLM
AMD MS RL J. Brown FJC XW CV JEO DL MM RP MRC PG TT PLP
C. Mulot FM A. Schneeweiss C. Sohn BB IT MJK NM JAK ST AMM
NVB NNA TD HAC HD ME MGC JF J. Lissowska LB PD RAEMT C.
Seynaeve CJvA VNK SS AET CBA DY AL SM PR PP M. Barile PM
JWMM JMC A. Jager A. Jakubowska J. Lubinski KJB KD C. McLean TB
YDK VA C. Stegmaier A. Swerdlow AA NO MJ J. Simard MD KP AJV
MG VK MKB JD VMK JMH kConFab Investigators Australian Ovarian
Cancer Study Group The GENICA Network. Wrote the paper: SK HN
RLM AC. Provided critical review of the manuscript: SK HN DG KM
GCT AC RLM PDPP UH MKS A. Meindl RW TH CB K. Aaltonen
GGG DFE PAF MJH ILA H. Brauch QW EJS H. Brenner AKD MSG FL
TAM K. Aittoma¨ki J. Liu PH AI KH J. Li KC JCC RH AR PS DFJ OF JP
IdSS NJ LG ZA JLH HT M. Bui EM DFS MCS CA J. Stone HMH MAA
RBvdL A. Mannermaa RKS BMM PL CT NR SJC DJH SSC MWRR
AB LJVV FBH MGS ABE MWB SEB BGN SFN HF PMZ JIAP J.
Benitez CAH BEH FS LLM AMD MS RL J. Brown FJC XW CV JEO
DL MM RP MRC PG TT PLP C. Mulot FM A. Schneeweiss C. Sohn BB
IT MJK NM JAK ST AMM NVB NNA TD HAC HD ME MGC JF J.
Lissowska LB PD RAEMT C. Seynaeve CJvA VNK SS AET CBA DY AL
PLOS ONE | www.plosone.org 10 November 2014 | Volume 9 | Issue 11 | e109973
MicroRNA Related Polymorphisms and Breast Cancer Risk
SM PR PP M. Barile PM JWMM JMC A. Jager A. Jakubowska J. Lubinski
KJB KD C. McLean TB YDK VA C. Stegmaier A. Swerdlow AA NO MJ
J. Simard MD KP AJV MG VK MKB JD VMK JMH kConFab
Investigators Australian Ovarian Cancer Study Group The GENICA
Network. Approved the final version of the manuscript: SK HN DG KM
GCT AC RLM PDPP UH MKS A. Meindl RW TH CB K. Aaltonen
GGG DFE PAF MJH ILA H. Brauch QW EJS H. Brenner AKD MSG FL
TAM K. Aittoma¨ki J. Liu PH AI KH J. Li KC JCC RH AR PS DFJ OF JP
IdSS NJ LG ZA JLH HT M. Bui EM DFS MCS CA J. Stone HMH MAA
RBvdL A. Mannermaa RKS BMM PL CT NR SJC DJH SSC MWRR
AB LJVV FBH MGS ABE MWB SEB BGN SFN HF PMZ JIAP J.
Benitez CAH BEH FS LLM AMD MS RL J. Brown FJC XW CV JEO
DL MM RP MRC PG TT PLP C. Mulot FM A. Schneeweiss C. Sohn BB
IT MJK NM JAK ST AMM NVB NNA TD HAC HD ME MGC JF J.
Lissowska LB PD RAEMT C. Seynaeve CJvA VNK SS AET CBA DY AL
SM PR PP M. Barile PM JWMM JMC A. Jager A. Jakubowska J. Lubinski
KJB KD C. McLean TB YDK VA C. Stegmaier A. Swerdlow AA NO MJ
J. Simard MD KP AJV MG VK MKB JD VMK JMH kConFab
Investigators Australian Ovarian Cancer Study Group The GENICA
Network. Administrative technical or material support: MKB JD MS RL.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000)
Environmental and heritable factors in the causation of cancer—analyses of
cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78–
85.
3. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, et al.
(2012) Genome-wide association analysis identifies three new breast cancer
susceptibility loci. Nat Genet 44: 312–318.
4. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, et al. (2013)
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
Nat Genet 45: 353–361, 361e351–352.
5. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ (2004) Processing of
primary microRNAs by the Microprocessor complex. Nature 432: 231–235.
6. Lee Y, Ahn C, Han J, Choi H, Kim J, et al. (2003) The nuclear RNase III
Drosha initiates microRNA processing. Nature 425: 415–419.
7. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, et al. (2001) A
cellular function for the RNA-interference enzyme Dicer in the maturation of
the let-7 small temporal RNA. Science 293: 834–838.
8. Sosio M, Kloosterman H, Bianchi A, de Vreugd P, Dijkhuizen L, et al. (2004)
Organization of the teicoplanin gene cluster in Actinoplanes teichomyceticus.
Microbiology 150: 95–102.
9. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev
Genet 9: 102–114.
10. Shukla GC, Singh J, Barik S (2011) MicroRNAs: Processing, Maturation, Target
Recognition and Regulatory Functions. Mol Cell Pharmacol 3: 83–92.
11. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA
biogenesis, function and decay. Nat Rev Genet 11: 597–610.
12. Zhong X, Coukos G, Zhang L (2012) miRNAs in human cancer. Methods Mol
Biol 822: 295–306.
13. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian
mRNAs are conserved targets of microRNAs. Genome Res 19: 92–105.
14. Farazi TA, Hoell JI, Morozov P, Tuschl T (2013) MicroRNAs in Human
Cancer. Adv Exp Med Biol 774: 1–20.
15. Wang X, Chen X, Wang R, Xiao P, Xu Z, et al. (2013) microRNA-200c
modulates the epithelial-to-mesenchymal transition in human renal cell
carcinoma metastasis. Oncol Rep 30: 643–650.
16. Liang Z, Wu H, Xia J, Li Y, Zhang Y, et al. (2010) Involvement of miR-326 in
chemotherapy resistance of breast cancer through modulating expression of
multidrug resistance-associated protein 1. Biochem Pharmacol 79: 817–824.
17. Volinia S, Croce CM (2013) Prognostic microRNA/mRNA signature from the
integrated analysis of patients with invasive breast cancer. Proc Natl Acad
Sci U S A 110: 7413–7417.
18. Guo L, Zhao Y, Yang S, Cai M, Wu Q, et al. (2012) Genome-wide screen for
aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer.
Mol Biol Rep.
19. (2012) Comprehensive molecular portraits of human breast tumours. Nature
490: 61–70.
20. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, et al. (2008)
Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal
cancer. Carcinogenesis 29: 579–584.
21. Song F, Zheng H, Liu B, Wei S, Dai H, et al. (2009) An miR-502-binding site
single-nucleotide polymorphism in the 3’-untranslated region of the SET8 gene
is associated with early age of breast cancer onset. Clin Cancer Res 15: 6292–
6300.
22. Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E (2010) Single
nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/
ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer 127: 589–
597.
23. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, et al. (2010) Single-
nucleotide polymorphisms inside microRNA target sites influence tumor
susceptibility. Cancer Res 70: 2789–2798.
24. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D (2010) Patrocles: a
database of polymorphic miRNA-mediated gene regulation in vertebrates.
Nucleic Acids Res 38: D640–651.
25. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, et al. (2003) Familial
risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.
J Natl Cancer Inst 95: 448–457.
26. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, et al. (2006)
Inconsistent association between the STK15 F31I genetic polymorphism and
breast cancer risk. J Natl Cancer Inst 98: 1014–1018.
27. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, et al. (2007) A genome-
wide association study identifies alleles in FGFR2 associated with risk of sporadic
postmenopausal breast cancer. Nat Genet 39: 870–874.
28. Frank B, Hemminki K, Wappenschmidt B, Meindl A, Klaes R, et al. (2006)
Association of the CASP10 V410I variant with reduced familial breast cancer
risk and interaction with the CASP8 D302H variant. Carcinogenesis 27: 606–
609.
29. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, et al. (2008) Risk
of different histological types of postmenopausal breast cancer by type and
regimen of menopausal hormone therapy. Int J Cancer 123: 933–941.
30. Li J, Humphreys K, Heikkinen T, Aittomaki K, Blomqvist C, et al. (2011) A
combined analysis of genome-wide association studies in breast cancer. Breast
Cancer Res Treat 126: 717–727.
31. Leu M, Humphreys K, Surakka I, Rehnberg E, Muilu J, et al. (2010) NordicDB:
a Nordic pool and portal for genome-wide control data. Eur J Hum Genet 18:
1322–1326.
32. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, et al. (2010) Genome-
wide association study identifies five new breast cancer susceptibility loci. Nat
Genet 42: 504–507.
33. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007)
Genome-wide association study identifies novel breast cancer susceptibility loci.
Nature 447: 1087–1093.
34. Liang D, Meyer L, Chang DW, Lin J, Pu X, et al. (2010) Genetic variants in
MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk,
survival, and treatment response. Cancer Res 70: 9765–9776.
35. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A (2000) Interferon-gamma
treatment elevates caspase-8 expression and sensitizes human breast tumor cells
to a death receptor-induced mitochondria-operated apoptotic program. Cancer
Res 60: 5673–5680.
36. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, et al. (2011) Genome-
wide association study identifies three new melanoma susceptibility loci. Nat
Genet 43: 1108–1113.
37. de Martino M, Haitel A, Schatzl G, Klingler HC, Klatte T (2013) The CASP8 -
652 6N Insertion/Deletion Promoter Polymorphism Is Associated with Renal
Cell Carcinoma Risk and Metastasis. J Urol.
38. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, et al.
(2007) A common coding variant in CASP8 is associated with breast cancer risk.
Nat Genet 39: 352–358.
39. Peng S, Lu B, Ruan W, Zhu Y, Sheng H, et al. (2011) Genetic polymorphisms
and breast cancer risk: evidence from meta-analyses, pooled analyses, and
genome-wide association studies. Breast Cancer Res Treat 127: 309–324.
40. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, et al.
(2004) Association of a common variant of the CASP8 gene with reduced risk of
breast cancer. J Natl Cancer Inst 96: 1866–1869.
41. Frank B, Bermejo JL, Hemminki K, Klaes R, Bugert P, et al. (2005) Re:
Association of a common variant of the CASP8 gene with reduced risk of breast
cancer. J Natl Cancer Inst 97: 1012; author reply 1012–1013.
42. Lin WY, Camp NJ, Ghoussaini M, Beesley J, Michailidou K, et al. (2014)
Identification and characterization of novel associations in the CASP8/
ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet.
43. Sun D, Lee G, Lee JH, Kim HY, Rhee HW, et al. (2010) A metazoan ortholog
of SpoT hydrolyzes ppGpp and functions in starvation responses. Nat Struct
Mol Biol 17: 1188–1194.
44. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, et al. (2008) Systematic
bioinformatic analysis of expression levels of 17,330 human genes across 9,783
samples from 175 types of healthy and pathological tissues. Genome Biol 9:
R139.
45. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. Cell
120: 15–20.
46. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site
accessibility in microRNA target recognition. Nat Genet 39: 1278–1284.
47. Sung H, Lee KM, Choi JY, Han S, Lee JY, et al. (2011) Common genetic
polymorphisms of microRNA biogenesis pathway genes and risk of breast
cancer: a case-control study in Korea. Breast Cancer Res Treat 130: 939–951.
PLOS ONE | www.plosone.org 11 November 2014 | Volume 9 | Issue 11 | e109973
MicroRNA Related Polymorphisms and Breast Cancer Risk
48. Birrer MJ, Segal S, DeGreve JS, Kaye F, Sausville EA, et al. (1988) L-myc
cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol 8:
2668–2673.
49. Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, et al. (2003) Amplification and
overexpression of the L-MYC proto-oncogene in ovarian carcinomas.
Am J Pathol 162: 1603–1610.
50. Xiong F, Wu C, Chang J, Yu D, Xu B, et al. (2011) Genetic variation in an
miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung
cancer. Cancer Res 71: 5175–5181.
51. Lombardo F, Komatsu D, Hadjiargyrou M (2004) Molecular cloning and
characterization of Mustang, a novel nuclear protein expressed during skeletal
development and regeneration. FASEB J 18: 52–61.
52. Kapushesky M, Adamusiak T, Burdett T, Culhane A, Farne A, et al. (2012)
Gene Expression Atlas update—a value-added database of microarray and
sequencing-based functional genomics experiments. Nucleic Acids Res 40:
D1077–1081.
53. Witkos TM, Koscianska E, Krzyzosiak WJ (2011) Practical Aspects of
microRNA Target Prediction. Curr Mol Med 11: 93–109.
PLOS ONE | www.plosone.org 12 November 2014 | Volume 9 | Issue 11 | e109973
MicroRNA Related Polymorphisms and Breast Cancer Risk
